Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt Pathway Activated Solid Tumors Where No Other Treatments Exist

Next Previous
Trial Profile

An Open Label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt Pathway Activated Solid Tumors Where No Other Treatments Exist

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DPTX 3186 (Primary)
  • Indications Colorectal cancer; Gastric cancer; Lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Dewpoint Therapeutics

Most Recent Events

  • 16 Jan 2026 Last checked against ClinicalTrials.gov record.
  • 12 Jan 2026 Planned initiation date changed from 16 Dec 2025 to 1 Jan 2026.
  • 12 Jan 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top